Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Equity Premium Income ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 9.3× Crispr Therapeutics AG's market cap, and JPMorgan Equity Premium Income ETF is more actively traded (3,820,809 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| CRSP | JEPI | |
|---|---|---|
Market Cap | $4.88B | $45.55B |
Volume | 2,861,747 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $73.97 | $59.88 |
52-Week Low | $44.34 | $55.29 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
JEPI trades at $56.67, up 0.39% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend distributions with recent payments of $0.37 in August and July 2026. Media coverage focuses on income strategies and tax implications, with Seeking Alpha highlighting JEPI's role as a hedge against tech-led market declines.
The outlook remains income-focused with steady monthly distributions, though covered-call strategies may limit upside during rallies. Key risks include interest rate sensitivity and tax inefficiencies, while institutional interest continues with Envestnet increasing its stake by 20.9% in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
